#5 Oral anticoagulant Drugs for Treating and Preventing Thrombosiss

Overview

Newer anticoagulant treatments are being introduced with the goal of curbing complications such as bleeding and thrombosis.
 
In the past year, increasing experience has been obtained with new generation oral anti-coagulants (such as anti-Factor X) in various stages of clinical trials. Compared to existing therapies, these agents continue to hold great promise for providing effective anticoagulation with decreased complications and easier monitoring.

Where Are They Now

New anticoagulant treatments are being introduced with the goal of curbing complications such as bleeding and thrombosis. Compared to existing therapies, these agents continue to hold great promise for providing effective anticoagulation for patients with atrial fibrillation or who are at risk for deep venous thrombosis.

There are now 3 Factor Xa inhibiting drugs available on the market, and along with dabigatran, these NOACs now account for 60% of the market that previously belonged to therapies such as warfarins. In a 2016 publication, oral anticoagulants were cited as the most responsible for emergency hospitalizations due to adverse drug bleeding as well as the most emergency room visits due to an adverse drug event and the most common cause of death associated with an adverse drug event. Several more oral anticoagulant drugs received FDA approval in 2017.

Get In Touch With Us